Spelling suggestions: "subject:"communityacquired pneumonia"" "subject:"communitycentred pneumonia""
21 |
Análise do impacto na redução de pneumonia adquirida na comunidade em crianças após a introdução da vacina antipneumocócica 10-valente no Programa Nacional de Imunização / Impact Analysis in reducing pneumonia acquired in the community in children after the introduction of 10-valent pneumococcal vaccine in the National Immunization ProgramSandra Rodrigues da Silva 31 March 2015 (has links)
O Streptococcus pneumoniae (pneumococo) constitui um dos mais importantes patógenos bacterianos do trato respiratório, podendo causar infecções invasivas e não invasivas, levando a altas taxas de morbimortalidade, particularmente em crianças menores de cinco anos de idade. A bactéria ganha acesso ao hospedeiro através da colonização da nasofaringe, que representa um importante reservatório para a transmissão deste patógeno na comunidade, contribuindo para a disseminação horizontal de pneumococo entre os indivíduos de uma população. As doenças respiratórias causadas por pneumococo constituem em uma das prioridades atuais em Saúde Pública, recebendo atenção destacada das organizações internacionais da área da saúde, como a Organização Mundial da Saúde. No presente trabalho procura-se conhecer e avaliar a ocorrência da pneumonia adquirida na comunidade (PAC) antes e após a implantação no Calendário Vacinal da Vacina Pneumocócica-10 Valente Conjugada em 2010, na área de abrangência da Superintendência Regional de Saúde (SRS) de Alfenas/MG. Foi realizado um estudo ecológico com componente temporal que incluiu registros de crianças menores que um ano de idade, vacinadas e não vacinadas com a vacina antipneumocócica 10-valente conjugada, no período pré e pós inclusão da vacina no PNI nos municípios da Superintendência Regional de Saúde (SRS) de Alfenas/MG, sendo a vacinação o fator de exposição e a ocorrência de PAC o desfecho, utilizando dados anuais secundários por município para cálculo da cobertura vacinal e das taxas de morbidade por pneumonia em menores de um ano no período de 2007 a 2013. Considerando se os 26 municípios da SRS de Alfenas, houve redução significativa do número de casos de PAC em crianças abaixo de um ano de idade, cuja Razão de Prevalência foi de 0,81 (IC95%: 0,74 0,89; p<0,05). Mesmo com um tempo reduzido de uso, a vacina pneumocócica conjugada 10 valente apresentou um impacto relevante na redução de PAC em crianças, ajustada por cobertura vacinal no período pós vacinação (2011-2013), sendo estatisticamente significativa na maioria dos municípios, o que sugere a efetividade da vacina PCV-10 na prevenção de casos da doença em crianças menores de um ano de idade. / The Streptococcus pneumoniae (pneumococcus) is one of the most important bacterial pathogens of the respiratory tract, may cause invasive and non-invasive infections, leading to high morbidity and mortality rates, particularly in children under five years of age. The bacteria gain access to the host through the nasopharyngeal colonization, which is an important reservoir for the transmission of this pathogen in the community, contributing to the horizontal spread among individuals in a population. Respiratory diseases caused by pneumococcus are in one of the current priorities in Public Health, receiving outstanding attention of international organizations in the health field, such as the World Health Organization. In the present study we aimed to understand and evaluate the occurrence of community acquired pneumonia (CAP) before and after implantation in 10- valent pneumococcal conjugate vaccine in 2010, on the coverage area of the Regional Health Service (SRS) of Alfenas / MG. An ecological study with temporal component was conducted which included records of children under one year old, vaccinated and not vaccinated with 10-valent pneumococcal conjugate vaccine, before and after period inclusion of the vaccine in PNI, in the municipalities of SRS of Alfenas / MG, with vaccination the exposure factor and the occurrence of CAP the outcome, using annual data side by municipality to calculate vaccination coverage and pneumonia morbidity in children under one year old, in the period 2007 to 2013. Considering the 26 municipalities of SRS Alfenas, there was a significant reduction in the number of CAP cases in children under one year old. The prevalence ratio was 0.81 (95%CI: 0.74 - 0.89; p<0.05). Even with a short period of use, the 10-valent pneumococcal conjugate vaccine had a significant impact on the reduction of CAP in children, adjusted for immunization coverage in the post vaccination period (2011-2013) and was statistically significant in most municipalities, which suggests the effectiveness of PCV-10 vaccine in preventing cases of the disease in children under one year of age.
|
22 |
Impact of guidelines for stratification of community acquired and hospital pneumonia severity and treatmentLiapikou, Adamantia 13 July 2012 (has links)
Treatment failure in community-acquired pneumonia (CAP) is the failure to normalize the clinical features (eg, fever, cough, sputum production), or nonresolving image in chest radiograph, despite antimicrobial therapy. The incidence of treatment failure in CAP has not been clearly established; according to several studies it ranges between 6% and 15%. The rate of mortality increases significantly, especially in those patients with severe CAP. It is important to be able to identify what patients are at risk for progressive or treatment failure pneumonia that may make them candidates for a more careful monitoring.
This doctoral thesis has been structured following the guidelines of the rules for submission of doctoral theses as a compendium of publications, adopted by the Council, Department of Medicine, University of Barcelona.
The studies are part of this thesis belong to the same line of research, validated the current guidelines of pneumonia-community acquired and hospital acquired. The results of the studies have provided relevant and innovative in this field and were collected in 2 original articles published in international journals with a widespread global impact factor of 16,37 points.
|
23 |
The treatment of community-acquired pneumonia in ambulatory patients / A systematic review and meta-analysis / Behandlung der ambulant erworbenen Pneumonie bei ambulanten Patienten / Eine systematische Übersicht und eine Meta-AnalyseBjerre, Lise M. 19 June 2003 (has links)
No description available.
|
24 |
Early post‑discharge mortality in CAP: frequency, risk factors and a prediction toolGlöckner, Verena, Pletz, Mathias W., Rohde, Gernot, Rupp, Jan, Witzenrath, Martin, Barten-Neiner, Grit, Kolditz, Martin 04 April 2024 (has links)
There are few data on mortality after discharge with community-acquired pneumonia (CAP). Therefore, we evaluated risk factors for 30-day post-discharge mortality after CAP. We included all patients of the prospective multi-national CAPNETZ study between 2002 and 2018 with (1) hospitalized CAP, (2) survival until discharge, and (3) complete follow-up data. The study endpoint was death within 30 days after discharge. We evaluated risk factors including demographics, comorbidities, admission CAP severity, and laboratory values and treatment-related factors in uni- and multivariable analyses. A total of 126 (1.6%) of 7882 included patients died until day 30 after discharge, corresponding to 26% of all 476 deaths. After multivariable analysis, we identified 10 independent risk factors: higher age, lower BMI, presence of diabetes mellitus, chronic renal or chronic neurological disease (other than cerebrovascular diseases), low body temperature or higher thrombocytes on admission, extended length of hospitalization, oxygen therapy during hospitalization, and post-obstructive pneumonia. By addition these factors, we calculated a risk score with an AUC of 0.831 (95%CI 0.822–0.839, p < 0.001) for prediction of post-discharge mortality. Early post-discharge deaths account for ¼ of all CAP-associated deaths and are associated with patient- and CAP-severity-related risk factors. Additional studies are necessary to replicate our findings in independent cohorts. Study registration: NCT 02139163.
|
25 |
Functional genomics of severe sepsis and septic shockRadhakrishnan, Jayachandran January 2013 (has links)
Sepsis is the systemic inflammatory response to an infection. Severe sepsis with multi organ failure is one of the commonest causes of admission to intensive care units, and is associated with poor early and late outcomes. The pathophysiology of sepsis is complex, and poorly understood. This is reflected in the limited and contentious treatment options for sepsis. Genetic factors have been shown to be associated with the risk of and subsequent outcomes from infection. However, clear associations with bacterial sepsis are rare, and even when associations are present their functional effects are often unknown. Gene expression signatures in sepsis are investigated in this project using serial samples obtained from patients admitted to intensive care units with community-acquired pneumonia or faecal peritonitis. The evolving gene expression signatures that define the response to sepsis were identified with large changes seen in genes coding for ribosomal proteins RPS4Y1 and RPS26P54. The differences in the sepsis response between the two diagnostic classes were examined. The gene expression predictors of mortality in sepsis were determined and include genes from the class II MHC HLA-DRB4, HLA-DRB5 and the T cell differentiation protein MAL. The effects of important covariates on gene expression were investigated and their impact on survival related expression determined. The findings were confirmed in a validation cohort. A novel clustering of samples representing distinct inflammatory patterns in a clinically homogeneous population of sepsis patients was identified and related to differences in clinical behaviour. The biological relevance of the differentially expressed genes was ascertained by identifying enriched gene sets. The gene expression changes in sepsis were examined in the context of related clinically relevant immune phenomena: the sterile systemic inflammatory response in patients undergoing elective cardiac surgery and the phenomenon of endotoxin tolerance in PBMCs derived from healthy volunteers. The results highlight the complexities of clinical sepsis and identify hypotheses for future investigations.
|
26 |
Retrospective Cohort Study of the Efficacy of Azithromycin Vs. Doxycycline as Part of Combination Therapy in Non-Intensive Care Unit Veterans Hospitalized with Community-Acquired PneumoniaSpivey, Justin, Sirek, Heather, Wood, Robert, Devani, Kalpit, Brooks, Billy, Moorman, Jonathan 01 October 2017 (has links)
The IDSA Community-Acquired Pneumonia (CAP) Guideline recommends ceftriaxone in combination with doxycycline as an alternative to combination therapy with ceftriaxone and azithromycin for non-intensive care unit (ICU) patients hospitalized with CAP. This is an attractive alternative regimen due to recent concerns of increased cardiovascular risk associated with azithromycin. The objective of this study was to compare the clinical outcomes of azithromycin and doxycycline each in combination with ceftriaxone for non-ICU Veterans hospitalized with CAP.
|
27 |
Impacto da vacina pneumocócica conjugada 10-valente (PCV10) na hospitalização de crianças por pneumonia em Goiânia: uso de dados primários e secundários / Assessing PCV10 impact in children hospitalized with pneumonia in Goiânia: using primary and secondary dataAndrade, Sabrina Sgambatti de 17 July 2015 (has links)
Submitted by Cássia Santos (cassia.bcufg@gmail.com) on 2015-11-12T12:16:48Z
No. of bitstreams: 2
Tese - Sabrina Sgambatti - 2015.pdf: 2847998 bytes, checksum: 069ae0ef61790cc3dd2564c3e7fa9120 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2015-11-12T12:21:22Z (GMT) No. of bitstreams: 2
Tese - Sabrina Sgambatti - 2015.pdf: 2847998 bytes, checksum: 069ae0ef61790cc3dd2564c3e7fa9120 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2015-11-12T12:21:22Z (GMT). No. of bitstreams: 2
Tese - Sabrina Sgambatti - 2015.pdf: 2847998 bytes, checksum: 069ae0ef61790cc3dd2564c3e7fa9120 (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Previous issue date: 2015-07-17 / Background. Anticipating the introduction of the 10-valent pneumococcal conjugate vaccine (PCV10) on childhood National Immunization Program (NIP), an active population-based surveillance on pneumonia hospitalizations was conducted as a baseline, enabling a vaccination impact study. The objectives of the present research were: (i) to assess the reliability of the Hospital Information System of the Unified Health System (SIH-SUS) as a data source for assessing PCV10 impact on pneumonia; (ii) to measure the impact of vaccination with PCV10 in reducing the incidence of clinical and X-Ray confirmed pneumonia, in children residing in Goiânia municipality.
Methods. In this study, we conducted an active prospective population-based surveillance on pneumonia in the post PCV10 vaccination period (2011-2013), in all 17 pediatric hospitals of Goiânia, with similar methodology used in the previous pneumonia surveillance during the pre vaccination period (2007-2009). Children aged 2-35 months of age, admitted to hospitalization with suspected diagnosis of pneumonia, were elegible for the survey. Clinical pneumonia and X-Ray confirmed pneumonia were the outcomes. The intervention was the PCV10, introduced in June 2010 in Goiania. Probabilistic linkage was performed between the SIH-SUS database (secondary data) and the active population surveillance (primary data) for the year 2012, to measure the agreement of case identification on pneumonia hospitalization rates between both data sources. To assess the impact of PCV10, annual incidence of clinical pneumonia and X-Ray confirmed pneumonia (per 100,000 population) and respective 95% confidence interval (95%CI) was estimated for the post vaccinations period and compared to the rates obtained for the pre vaccination period. The relative risk for pneumonia and respective 95%CI were calculated based on Poisson distribution. The percentage change in rates (1-relative risk) between pre and post vaccination periods was calculated.
Results. Pneumonia incidence rates obtained by the SIH-SUS were statistically similar to those obtained by active population surveillance for children 2-23meses (p = 0.184). On the PCV10 impact evaluation study, the rates of hospitalization for clinical and RXT confirmed pneumonia in children under 24 months decreased 13.1% (from 5,728/100,000 to 4,976/100,000) and 25.4% (from 2,497/100,000 to 1,862/100,000), respectively, after routine immunization. / Introdução. Antecipando a introdução da vacina pneumocócica conjugada 10-valente (PCV10) no calendário de vacinação infantil do Programa Nacional de Imunizações (PNI), um estudo de vigilância de base populacional ativa foi conduzido como linha de base, possibilitando, assim, avaliar o impacto da vacinação nas hospitalizações por pneumonia. Assim, os objetivos desta investigação foram: (i) avaliar a confiabilidade do Sistema de Informações Hospitalares do Sistema Único de Saúde (SIH-SUS) como fonte de dados para estudos de avaliação de impacto da PCV10 nas pneumonias; (ii) avaliar o impacto da vacinação com a PCV10 na redução da incidência de hospitalizações de crianças com pneumonia clínica e confirmada por Raio-X de tórax (RXT), residentes no município de Goiânia.
Métodos. Neste estudo, conduzimos uma vigilância populacional prospectiva, ativa, de pneumonias no período pós vacinal (2011-2013) em 17 hospitais pediátricos de Goiânia, com metodologia similar à conduzida em estudo anterior, no período pré vacinal (2007-2009). Foram elegíveis para o estudo crianças de 2 a 35 meses de idade, admitidas com com diagnóstico inicial de pneumonia. Os desfechos foram pneumonia clínica e pneumonia confirmada por RXT. A intervenção foi a PCV10, introduzida em junho de 2010 em Goiânia. A técnica de linkage probabilístico foi utilizada para vincular o banco de dados do SIH-SUS (dados secundários) e o da vigilância populacional ativa (dados primários) referentes ao ano de 2012, e desta forma, avaliar a concordância no diagnóstico e nas taxas de hospitalização por pneumonia entre as duas fontes de dados. Para avaliar o impacto da PCV10, calculou-se a incidência anual de pneumonia clínica e confirmada por RXT (por 100.000 habitantes) e respectivos intervalos de 95% de confiança (IC95%) para o período pós vacinal, e comparou-se com as taxas do período pré vacinal. O risco relativo para pneumonia e respectivos IC95% foram calculados com base na distribuição de Poisson. O percentual de mudança entre as taxas pré e pós vacinal foi calculado como 1-risco relativo.
Resultados. As taxas de pneumonia obtidas pelo SIH-SUS foram estatisticamente similares às obtidas por vigilância populacional ativa para as crianças de 2-23meses (p=0,184). No estudo de avaliação do impacto da PCV10, as taxas de hospitalização por pneumonia clínica e confirmada por RXT em crianças menores de 24 meses reduziram 13.1% (de 5,728/100,000 para 4,976/100,000) e 25.4% (de 2,497/100,000 para 1,862/100,000), respectivamente, após a vacinação de rotina.
Conclusões. Dados do SIH-SUS podem ser utilizados para avaliar o impacto da PCV10 nas hospilazações por pneumonia na infância. Após 3 anos de vacinação com a PCV10 em Goiânia, observou-se significante queda das taxas de hospitalização por pneumonia clinica e confirmada por RXT em crianças alvo do PNI.
|
28 |
CLINICAL SEVERITY OF RHINOVIRUS/ENTEROVIRUS COMPARED TO OTHER RESPIRATORY VIRUSES IN CHILDRENAsner, Andrea Sandra 10 1900 (has links)
<p><strong>Background</strong>: Human rhinovirus/enterovirus (HRV/ENT) infections are commonly identified in children with acute respiratory infections (ARIs), but data on their clinical severity remains limited. We compared the clinical severity of HRV/ENT to respiratory syncytial virus (RSV), influenza A/B (FLU) and other common respiratory virus in children.</p> <p><strong>Methods</strong>: Retrospective study of children with ARIs and confirmed single positive viral infections on mid-turbinate swabs by molecular assays. Outcome measures included hospital admission and, for inpatients, a composite end-point consisting of intensive care admission, hospitalization greater than 5 days, oxygen requirements or death.</p> <p><strong>Results</strong>: A total of 116 HRV/ENT, 102 RSV, 99 FLU and 64 other common respiratory viruses were identified. Children with single HRV/ENT infections presented with significantly higher rates of underlying immunosuppressive conditions compared to those with RSV (37.9% vs 13.6%; p</p> <p><strong>Conclusions</strong>: Children with HRV/ENT had a more severe clinical course than those with RSV and FLUA/B infections and often had significant comorbidities. These findings emphasize the importance of considering HRV/ENT infection in children presenting with severe acute respiratory tract infections.</p> / Master of Science (MSc)
|
Page generated in 0.0731 seconds